ArticleNPJ breast cancer2019
Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.
Article in NPJ breast cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Neighborhood deprivation and oncotype DX recurrence scores among Black and White women: the interplay between race, place, and tumor biology.NPJ breast cancer · 2026Article
- Identification of racial disparities across MammaPrint and BluePrint subtypes in HR + HER2- breast cancer.NPJ breast cancer · 2026Article
- Cost-effectiveness analysis of gene-expression-based prognostic tests for patients with early-stage breast cancer in South Korea.Cost effectiveness and resource allocation : C/E · 2025Article
- A registry-based approach for estimating county-level race disparities in breast cancer mortality: an analysis in Georgia.American journal of epidemiology · 2025Article
- Genetic Ancestry and 21-Gene Oncotype DX Breast Cancer Recurrence Scores.Annals of surgical oncology · 2025Article
- Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii.The breast journal · 2025Article
- Development and validation of a clinical breast cancer tool for accurate prediction of recurrence.NPJ breast cancer · 2024Article
- Article
- Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.JAMA network open · 2023Article
- Differential distribution of actual and surrogate oncotype DX recurrence scores in breast cancer patients by age, menopausal status, race, and body mass index.Breast cancer research and treatment · 2023Article
- Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.Cancers · 2023Article
- Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer.International journal of environmental research and public health · 2023Review
- Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression.Breast cancer research and treatment · 2022Article
- Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer.NPJ breast cancer · 2021Article
- Neighborhood-Level Redlining and Lending Bias Are Associated with Breast Cancer Mortality in a Large and Diverse Metropolitan Area.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.BMC cancer · 2020Article
- Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia.NPJ breast cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
Among women diagnosed with stage I-IIIa, node-negative, hormone receptor (HR)-positive breast cancer (BC), Oncotype DX recurrence scores (ODX RS) inform chemotherapy treatment decisions. Differences in recurrence scores or testing may contribute to racial disparities in BC mortality among women with HR+ tumors. We identified 12,081 non-Hispanic White (NHW) and non-Hispanic Black (NHB) BC patients in Georgia (2010-2014), eligible to receive an ODX RS. Logistic regression was used to estimate the odds of chemotherapy receipt by race and ODX RS. Cox proportional hazard regression was used to calculate the hazard ratios (HRs) comparing BC mortality rates by race and recurrence score. Receipt of Oncotype testing was consistent between NHB and NHW women. Receipt of chemotherapy was generally comparable within strata of ODX RS-although NHB women with low scores were slightly more likely to receive chemotherapy (OR = 1.16, 95% CI 0.77, 1.75), and NHB women with high scores less likely to receive chemotherapy (OR = 0.77, 95% CI 0.48, 1.24), than NHW counterparts. NHB women with a low recurrence score had the largest hazard of BC mortality (HR = 2.47 95% CI 1.22, 4.99) compared to NHW women. Our data suggest that additional tumor heterogeneity, or other downstream treatment factors, not captured by ODX, may be drivers of racial disparities in HR+ BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.